<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581876</url>
  </required_header>
  <id_info>
    <org_study_id>CSPAC-24</org_study_id>
    <nct_id>NCT04581876</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer</brief_title>
  <official_title>A Single-arm, Prospective Study to Evaluate the Safety and Efficacy and of the Combination of Raltitrexed for Injection and Nab-Paclitaxel as Second-line Therapy in Treating Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is intended to investigate the safety and efficacy of the patients with&#xD;
      confirmed advanced pancreatic cancer after treating with the combination of raltitrexed for&#xD;
      injection and nab-paclitaxel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conditions: Advanced pancreatic cancer subjects which were prospectively to receive&#xD;
      first-line chemotherapy.&#xD;
&#xD;
      Keywords: Advanced pancreatic cancer; paclitaxel liposome; S-1 Interventions: Drug:&#xD;
      paclitaxel liposome; Drug:S-1 Phase: Phase IV Study Type: Interventional&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Allocation: Non-randomized Endpoint Classification: Efficacy/ Safety Study Intervention&#xD;
      Model: single arm Primary Purpose: Treatment MedlinePlus related topics: Cancer, Pancreatic&#xD;
      Cancer Drug Information available for: paclitaxel liposome：paclitaxel liposome for injection&#xD;
      S-1：Tegafur, Gimeracil and Oteracil Potassium Capsules&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      To evaluate the Progression Free Survival of patients with advanced pancreatic cancer after&#xD;
      treated with paclitaxel liposome plus S-1.&#xD;
&#xD;
      Secondary Outcome Measures:&#xD;
&#xD;
      To evaluate the Overall Response Rate、overall survival、disease control rate、Quality of&#xD;
      Life、adverse events of patients with advanced pancreatic cancer after treated with paclitaxel&#xD;
      liposome plus S-1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 36 months</time_frame>
    <description>To evaluate the objective response rate of patients with advanced pancreatic cancer after treated with raltitrexed for injection plus nab-paclitaxel as second-line therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>To evaluate progression free survival of patients with advanced pancreatic cancer after treated with raltitrexed for injection plus nab-paclitaxel as second-line therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>To evaluate the overall survival of patients with advanced pancreatic cancer after treated with raltitrexed for injection plus nab-paclitaxel as second-line therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>up to 36 months</time_frame>
    <description>To evaluate the adverse events of patients with advanced pancreatic cancer after treated with raltitrexed for injection plus nab-paclitaxel as second-line therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>raltitrexed for injection + nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive raltitrexed 2mg/m2 (iv, 15min) and nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltitrexed for injection</intervention_name>
    <description>Patients receive raltitrexed 2mg/m2 (iv, 15min) on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.</description>
    <arm_group_label>raltitrexed for injection + nab-paclitaxel</arm_group_label>
    <other_name>raltitrexed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Patients receive nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.</description>
    <arm_group_label>raltitrexed for injection + nab-paclitaxel</arm_group_label>
    <other_name>albumin-bound paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed content obtained prior to treatment;&#xD;
&#xD;
          2. The patients were confirmed as advanced pancreatic cancer by histopathology or&#xD;
             cytology;&#xD;
&#xD;
          3. At least one measurable objective lesion was identified based on the RECIST 1.1&#xD;
             criteria;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;&#xD;
&#xD;
          5. The expected survival after surgery ≥3 months;&#xD;
&#xD;
          6. Subjects had good compliance, were able to undergo treatment and follow-up, and&#xD;
             voluntarily followed the relevant regulations of this study;&#xD;
&#xD;
          7. No contraindications to the use of raltitrexed for injection and nab-paclitaxel;&#xD;
&#xD;
          8. Age ≥18 years and ≤75 years;&#xD;
&#xD;
          9. Subjects of child-bearing age must agree to take effective contraceptive measures&#xD;
             during the study period; Serum or urine pregnancy tests must be negative for women of&#xD;
             childbearing age 7 days before the start of chemotherapy, during the monthly treatment&#xD;
             interval and after the last treatment;&#xD;
&#xD;
         10. Women must be non-lactating.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The target disease has cerebral metastasis;&#xD;
&#xD;
          2. The medical history and complications, which may affect patients' ability to&#xD;
             participate in the study and their safety during the study, or interfere with&#xD;
             explanation of the study results, for example: severe cardiovascular and&#xD;
             cerebrovascular diseases, uncontrolled diabetes, uncontrolled hypertension,&#xD;
             uncontrolled infection, active peptic ulcer, etc.;&#xD;
&#xD;
          3. Dementia, altered mental state, or any mental illness that prevents understanding or&#xD;
             informed consent or questionnaires;&#xD;
&#xD;
          4. History of allergy or hypersensitivity to any therapeutic ingredient;&#xD;
&#xD;
          5. Combined with other malignant tumors excepted pancreatic cancer within the first 5&#xD;
             years of admission, excepted cured basal cell or squamous cell carcinoma of the skin,&#xD;
             local prostate cancer after radical surgery, ductal carcinoma in situ after radical&#xD;
             surgery;&#xD;
&#xD;
          6. Subjects with peripheral neuropathy ≥2 according to CTCAE version 5.0;&#xD;
&#xD;
          7. Physical examination or laboratory examination results are abnormal;&#xD;
&#xD;
               1. Hematological dysfunction is defined as: i) absolute neutrophil (ANC) count &lt;1.5&#xD;
                  × 109 / L; ii) platelet (PLT) count: &lt;100 × 109 / L; iii) hemoglobin (Hb)&#xD;
                  level&lt;90g / L;&#xD;
&#xD;
               2. Hepatic abnormalities are defined as: i) total bilirubin (TBil) levels: &gt;1.5&#xD;
                  times the upper limit of normal (ULN); ii) aspartate aminotransferase (AST) and&#xD;
                  alanine aminotransferase (ALT) levels &gt;2.5 times the ULN &gt;5 times ULN if liver&#xD;
                  metastases are present;&#xD;
&#xD;
               3. Definition of renal dysfunction: serum creatinine &gt;1.5 times ULN, or calculated&#xD;
                  creatinine clearance &lt;50ml / min;&#xD;
&#xD;
               4. Definition of abnormal blood coagulation function: International Normalized Ratio&#xD;
                  (INR) &gt;1.5 times of ULN, and prothrombin time (PT) or activated partial&#xD;
                  thromboplastin time (aPTT) &gt;1.5 times of ULN, unless the subject is receiving&#xD;
                  anti-antibodies Coagulation treatment.&#xD;
&#xD;
          8. Hepatitis B surface antigen positive (HBsAg), and subjects with peripheral blood&#xD;
             hepatitis B virus DNA (HBV-DNA) titer ≥1×103 copies / L; if HBsAg is positive, and&#xD;
             peripheral blood HBV-DNA &lt;1×103 copy number / L, if the researcher believes that the&#xD;
             subject's chronic hepatitis B is in a stable phase and does not increase the risk of&#xD;
             the subject, the subject is eligible for selection;&#xD;
&#xD;
          9. Hepatitis C virus (HCV) or human immunodeficiency virus (HIV) positive;&#xD;
&#xD;
         10. Patients who need to combine other anti-tumor drugs;&#xD;
&#xD;
         11. Participation in any trial drug treatment or another interventional clinical trial 30&#xD;
             days before screening period.&#xD;
&#xD;
         12. Other conditions that researchers not think to be suitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xian-Jun Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xian-Jun Yu, MD, PhD</last_name>
    <phone>+86 21 64175590</phone>
    <email>wangwenquan@fudanpci.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Quan Wang</last_name>
      <phone>+86 21 64175590</phone>
      <email>wangwenquan@fudanpci.org</email>
    </contact>
    <investigator>
      <last_name>Xian-Jun Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 3, 2020</last_update_submitted>
  <last_update_submitted_qc>October 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xian-Jun Yu</investigator_full_name>
    <investigator_title>Vice President</investigator_title>
  </responsible_party>
  <keyword>Advanced pancreatic cancer</keyword>
  <keyword>raltitrexed for injection</keyword>
  <keyword>nab-paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

